EUVIMEDEUVIMED entdecken
Crossref

Prospective multicenter study of EUS-guided hepaticogastromy with antegrade stent placement in patients with unresectable malignant biliary obstruction

M Itonaga, H Imai, K Takeshita, R Sagami, H Shiomi, K Kitagawa, S Sugimori, T Ikeura, M Asada, T Ogura, K Matsumoto, H Nishikiori und 13 weitere

Endoscopy · 01.06.2026 · 58 (S 03 S 03) · S102-S103

DOI: 10.1055/s-0046-1820804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.06.2026. Verfasst von M Itonaga und 24 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Although several cohort studies [ 1 ] [ 2 ] [ 3 ] have reported that EUS-guided hepaticogastromy with antegrade placement (EUS-HGAS) prolongs time to recurrent biliary obstruction (TRBO) compared with EUS-HGS alone, prospective evidence remains unavailable. We conducted a multicenter prospective study to evaluate the outcomes of EUS-HGAS for unresectable malignant biliary obstruction (MBO) and further compared the results with historical data of EUS-HGS.

Methods

This present study involved 24 referral centers in Japan. Patients scheduled to undergo EUS-HGAS for unresectable malignant biliary obstruction (MBO) after failed endoscopic retrograde cholangiopancreatography (ERCP) between October 2022 and February 2025 were prospectively enrolled. In this procedure, an uncovered metal stent (MS) was used as the antegrade stent, and either a plastic stent or a covered MS was placed at the EUS-guided access route. Clinical assessments and blood tests were performed on postoperative days 1, 3, 30, 90, and 180, and additional imaging studies, such as CT scans, were obtained when clinically indicated. For comparison, historical data on EUS-HGS using a covered MS for unresectable MBO after failed ERCP were collected from the participating institutions for the period between April 2018 and March 2022. A matched cohort with balanced baseline characteristics was created using 1:2 propensity score matching to compare the EUS-HGAS and EUS-HGS groups. The primary endpoint was TRBO, while secondary endpoints included technical success, clinical success, adverse events (AEs), recurrent biliary obstruction (RBO), procedure time, length of hospital stay, and overall survival.

Results

A total of 49 patients were prospectively enrolled in the EUS-HGAS group. Baseline characteristics were as follows: 57% male, median age 76 years, ECOG performance status 0 in 24%, pancreatic cancer as the primary malignancy in 55%, distal biliary obstruction in 86%, surgically altered anatomy in 35%, duodenal obstruction in 59%, preprocedural cholangitis in 18%, and ascites in 16%. The technical and clinical success rates were 73% (36/49) and 92% (33/36), respectively. Early and late adverse event (AE) rates were 12% (6/49; three cases of acute pancreatitis and three of bile peritonitis) and 2% (1/49; acute cholecystitis), respectively. The RBO rate was 6% (2/36). The median procedure time was 40 minutes (interquartile range [IQR], 26–50), and the median length of hospital stay was 13 days (IQR, 8–18). In the EUS-HGS group, 414 patients were identified. In the prematched cohort, significant differences were observed between the two groups in primary cancer site, site of biliary obstruction, surgically altered anatomy, preprocedural cholangitis, and the presence of ascites. After matching, no significant differences in baseline characteristics were observed between the two groups. Ultimately, 44 patients in the EUS-HGAS group and 88 in the EUS-HGS group were included in the matched cohort. The technical success rate was significantly lower in the EUS-HGAS group (70% vs. 95%, P

Zitieren

APA

Itonaga, M., Imai, H., Takeshita, K., Sagami, R., Shiomi, H., Kitagawa, K., Sugimori, S., Ikeura, T., Asada, M., Ogura, T., Matsumoto, K., Nishikiori, H., Takenaka, M., Shigekawa, M., Fujimori, N., Shimatani, M., Kuroda, T., Kinosita, M., Shintani, S., …, & Kitano, M. (2026). Prospective multicenter study of EUS-guided hepaticogastromy with antegrade stent placement in patients with unresectable malignant biliary obstruction. Endoscopy, 58(S 03 S 03), S102-S103. https://doi.org/10.1055/s-0046-1820804

Vancouver

Itonaga M, Imai H, Takeshita K, Sagami R, Shiomi H, Kitagawa K, et al. Prospective multicenter study of EUS-guided hepaticogastromy with antegrade stent placement in patients with unresectable malignant biliary obstruction. Endoscopy. 2026;58(S 03 S 03):S102-S103. doi:10.1055/s-0046-1820804

BibTeX
@article{Itonaga2026,
  author = {Itonaga, M and Imai, H and Takeshita, K and Sagami, R and Shiomi, H and Kitagawa, K and Sugimori, S and Ikeura, T and Asada, M and Ogura, T and Matsumoto, K and Nishikiori, H and Takenaka, M and Shigekawa, M and Fujimori, N and Shimatani, M and Kuroda, T and Kinosita, M and Shintani, S and Kamada, H and Koizumi, M and Takeda, Y and Ishida, Y and Mandai, K and Kitano, M},
  title = {Prospective multicenter study of EUS-guided hepaticogastromy with antegrade stent placement in patients with unresectable malignant biliary obstruction},
  journal = {Endoscopy},
  year = {2026},
  volume = {58},
  number = {S 03 S 03},
  pages = {S102--S103},
  doi = {10.1055/s-0046-1820804}
}
Kostenlos starten →